1. ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT. (12th June 2019) Authors: Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y.H.; Manni, M.; Horwitz, S.M.; Antonio De Souza, C.; Radford, J.; Varela, S.B.; Prates, M.V.; Ferreri, A.; Chiattone, C.; Spina, M.; Vose, J.M.; Chiappella, A.; Laszlo, D.; Marino, D.; Stelitano, C.; Skrypets, T. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL. (June 2017) Authors: Ferrero, S.; Rossi, D.; Bruscaggin, A.; Evangelista, A.; Di Rocco, A.; Spina, V.; Stefoni, V.; Ghione, P.; Barbero, D.; Monitillo, L.; Gomes Da Silva, M.; Santoro, A.; Molinari, A.; Ferreri, A.; Piccin, A.; Cortelazzo, S.; Ladetto, M.; Gaidano, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY. (June 2017) Authors: Carlo‐Stella, C.; Barde, P.; Delarue, R.; Scarfò, L.; Viswanadha, S.; Locatelli, S.; Gandolfi, S.; Pittari, V.; Morello, L.; Magagnoli, M.; Pilipow, K.; De Paoli, F.; Lugli, E.; Santoro, A.; Ferreri, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗